Add like
Add dislike
Add to saved papers

Eat, Sleep, Console improves medical readiness in neonatal opioid withdrawal syndrome

2 Minute Medicine 2023 July 14

1. In this randomized controlled trial, the Eat, Sleep, Console approach resulted in a significantly shortened time to medical readiness for discharge in neonates with opioid withdrawal syndrome. 

2. There was no significant difference between usual care and the Eat, Sleep, Console approach in the incidence of adverse outcomes. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Neonatal opioid withdrawal syndrome results from exposure to opioids in utero. Clinical signs can include seizures, irritability, and gastrointestinal issues. Historically, subjective and observation-based scoring systems such as the Finnegan Neonatal Abstinence Scoring Tool have been used to determine which infants with neonatal opioid withdrawal syndrome receive treatment. However, a focal criticism of this approach is that it overestimates the need for infants to be treated pharmacologically. A newer care tool, known as the Eat, Sleep Console approach, shifts the focus to a functional assessment of the infant paired with prioritization of non-pharmacological means of treatment and a focus on caregiver empowerment. The focus of this multi-center, cluster-randomized trial was to evaluate the efficacy and safety of this new approach compared to usual care. The primary results of the study found that the Eat, Sleep, Console approach helped to significantly shorten the time between birth to when neonates were medically ready for discharge compared to usual care. Further, it did not demonstrate an increased risk of adverse safety outcomes compared to usual care. A primary limitation of the study is the unmasked design. Overall, the Eat, Sleep, Console approach is an effective means of reducing time to discharge for patients with neonatal opioid withdrawal syndrome.

Click to read the study in NEJM

In-Depth [randomized controlled trial]: This was a cluster-randomized, unmasked, controlled trial evaluating the effect of the Eat, Sleep, Console care approach on time-to-discharge for neonates with opioid withdrawal syndrome. The primary outcome of interest was the time from birth to medical readiness for discharge, with secondary outcomes of interest including the total length of stay, receipt of pharmacological treatment, and safety outcomes. Infants born full-term with evidence of antenatal opioid exposure and who were undergoing treatment for opioid withdrawal were included in the study. Participants were randomized by sites into one of eight blocks, with the overall study including a total of 1,305 infants. Primary results of the analysis found that the Eat, Sleep, Console group demonstrated a significantly shorter time between birth until medically ready for discharge compared to the usual-care group (adjusted mean difference, 6.7 days; 95% Confidence Interval [CI], 4.7 to 8.8). The Eat, Sleep, Console group also demonstrated a shorter mean length of hospital stay compared to usual care (rate ratio, 0.56; 95% CI, 0.49 to 0.64). There was no difference in safety outcomes between the groups. In summary, this study provided evidence that the Eat, Sleep, Console approach may be superior to usual care with respect to shortening the length of time between birth to medical readiness for discharge, and total length of stay, with no differences in risk of adverse outcomes. Long-term follow-up of the infants will provide greater insight into safety outcomes following discharge.

Originally Published By 2 Minute Medicine®. Reused on Read by QxMD with permission.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Add to Saved Papers

Get 1-tap access

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app